Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03505099 · ClinicalTrials.gov registry record · Phase 3
Pre-Symptomatic Study of Intravenous Onasemnogene Abeparvovec-xioi in Spinal Muscular Atrophy (SMA) for Patients With Multiple Copies of SMN2
A Phase 3 study, sponsored by Novartis Gene Therapies.
- Completed
- Registry status
- Phase 3
- Development phase
- 30
- Enrollment target
NCT03505099 is a Phase 3 study that has completed, run by Novartis Gene Therapies. The registered enrollment target is 30 participants.
The verdict
NCT03505099, a Phase 3 study, has completed, sponsored by Novartis Gene Therapies.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 30 participants
- Enrollment target
Study Summary
To evaluate the safety and efficacy of intravenous onasemnogene abeparvovec-xioi in pre-symptomatic patients with SMA and 2 or 3 copies SMN2
Interventions
- BIOLOGICAL onasemnogene abeparvovec-xioi
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2018-04-02 |
| Est. Completion | 2021-06-15 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03505099
The ClinicalTrials.gov registry entry for NCT03505099 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Gene Therapies, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which onasemnogene abeparvovec-xioi is the first listed.
NCT03505099 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03505099 about?
NCT03505099 is a clinical study titled "Pre-Symptomatic Study of Intravenous Onasemnogene Abeparvovec-xioi in Spinal Muscular Atrophy (SMA) for Patients With Multiple Copies of SMN2". To evaluate the safety and efficacy of intravenous onasemnogene abeparvovec-xioi in pre-symptomatic patients with SMA and 2 or 3 copies SMN2
What is the current status of trial NCT03505099?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 30 participants. The study started on 2018-04-02. Estimated completion is 2021-06-15.
What interventions are being tested in trial NCT03505099?
The interventions under investigation include: onasemnogene abeparvovec-xioi (BIOLOGICAL).
Who is sponsoring clinical trial NCT03505099?
This trial is sponsored by Novartis Gene Therapies, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.